"neoadjuvant chemoradiation therapy" trang 11 - tải miễn phí từ tailieunhanh
Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT

Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT
9    50    0
A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: Combining functional MRI and texture analysis

A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: Combining functional MRI and texture analysis
12    61    0
Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: A retrospective study

Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: A retrospective study
11    60    0
Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma

Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma
8    65    0
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
9    58    0
Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: A multicenter, randomized controlled trial (KONCLUDE)

Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: A multicenter, randomized controlled trial (KONCLUDE)
8    44    1
Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy

Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy
12    84    1
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation
11    46    1
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy

Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy
10    61    1
Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer

Predicting prognosis according to preoperative chemotherapy response in patients with locally advanced lower rectal cancer
9    24    1
A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study
15    70    1
Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: A propensity score-matched analysis

Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: A propensity score-matched analysis
10    61    1
Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy

Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
12    68    1
Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxelbased chemotherapy in breast cancer patients

Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxelbased chemotherapy in breast cancer patients
13    51    1
Predictive value of lymphocyte-tomonocyte ratio in the preoperative setting for progression of patients with breast cancer

Predictive value of lymphocyte-tomonocyte ratio in the preoperative setting for progression of patients with breast cancer
9    32    1
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma

Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
7    29    1
Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing

Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing
13    43    1
Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: The INCREASE trial
10    63    1
Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?

Quantified MRI and 25OH-VitD3 can be used as effective biomarkers for patients with neoadjuvant chemotherapy-induced liver injury in CRCLM?
11    31    1
Adjuvant radiotherapy improves cause specific survival in stage II, not stage III mucinous carcinoma of the rectum

Adjuvant radiotherapy improves cause specific survival in stage II, not stage III mucinous carcinoma of the rectum
6    27    1